Skystar Bio-Pharmaceutical Company announced consolidated earnings results for the year ended December 31, 2013. Revenues totaled $42.5 million, a 26.5% increase compared to the $33.6 million in revenues reported for the full fiscal 2012 year. Net income increased 69.5% year over year to $10.5 million or $1.37 per fully diluted share, as compared to $6.2 million or $0.83 per fully diluted share in the year ago period. Income from operations was $13.012 million against $8.550 million a year ago. Income before provision for income taxes was $12.931 million against $8.380 million a year ago. Net cash used in operating activities was $5.423 million against net cash from operating activities of $6.546 million a year ago. Purchases of property, plant and equipment were $19,825 against $163.049 million a year ago.

For the year 2014, the company expects revenue range is $46 million to $50 million with gross margin of roughly 50% for fiscal 2014.